Cancer InsightPub Date : 2024-03-15DOI: 10.58567/ci03010005
Xingyi Wan, Mengyan Jiang, Shriya Madan
{"title":"Research progress of nanomedicine for tumor immunotherapy","authors":"Xingyi Wan, Mengyan Jiang, Shriya Madan","doi":"10.58567/ci03010005","DOIUrl":"https://doi.org/10.58567/ci03010005","url":null,"abstract":"Cancer, a pervasive threat to human health, presents formidable challenges to traditional treatment approaches. Tumor immunotherapy has emerged as a promising strategy for combating malignancies by bolstering the body's immune response to thwart tumor metastasis and recurrence. Nonetheless, the intricacies of tumors, patient heterogeneity, and the presence of tumor-immunosuppressive microenvironments have limited the overall efficacy of immunotherapy, achieving only approximately a 20% success rate. In recent years, nanomaterials have garnered increasing attention in the realm of tumor immunotherapy due to their inherent advantages, such as excellent biocompatibility, precise targeting, and controlled drug release. Nanomaterials empower immunostimulatory molecules and therapeutic agents with the ability to specifically target tumors, amplify drug accumulation at tumor sites, facilitate local immune modulation, alleviate immunosuppressive microenvironments, and thereby enhance the effectiveness of tumor immunotherapy. This review provides an overview of the current state of immunotherapy and offers insights into the ongoing research progress surrounding various nanomaterials aimed at augmenting the efficacy of immunotherapy.","PeriodicalId":476544,"journal":{"name":"Cancer Insight","volume":"18 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer InsightPub Date : 2024-03-15DOI: 10.58567/ci03010004
Hao Shen, Jiayu Ding, Jiaying Ji, Binjian Jiang, Xiao Wang, Peng Yang
{"title":"Overcoming MTDH and MTDH-SND1 complex: driver and potential therapeutic target of cancer","authors":"Hao Shen, Jiayu Ding, Jiaying Ji, Binjian Jiang, Xiao Wang, Peng Yang","doi":"10.58567/ci03010004","DOIUrl":"https://doi.org/10.58567/ci03010004","url":null,"abstract":"<p class=\"MsoNormal\" style=\"margin-top: 12pt; text-align: justify;\"><span style=\"font-family: arial, helvetica, sans-serif;\"><span lang=\"EN-US\">Metadherin (MTDH), also known as LYRIC or AEG-1, is an oncogene that enhances tumor progression, metastasis, drug resistance, and immune escape in various cancers by modulating multiple oncogenic pathways, including </span><span lang=\"EN-US\">NF-κB, PI3K/AKT, Wnt/β-catenin, MAPK, and AMPK</span><span lang=\"EN-US\">. Due to the unknown of the complete structure of MTDH, the deep mechanisms of MTDH and selective inhibitors targeting MTDH remain to be explored. The Protein-Protein interaction (PPI) with the Staphylococcal nuclease domain containing 1 (SND1) is a crucial mechanism underlying the function of MTDH. Current studies have demonstrated that inhibitors, including antisense oligonucleotides, peptides, and small molecules targeting MTDH or MTDH-SND1 interactions, provide novel strategies to inhibit the oncogenetic effects of MTDH. This review summarizes and discusses the structure, function, and regulation of MTDH in cancers, providing the potential therapeutic perspectives of MTDH or MTDH-SND1 PPI for drug discovery.</span></span></p>","PeriodicalId":476544,"journal":{"name":"Cancer Insight","volume":"14 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer InsightPub Date : 2024-03-15DOI: 10.58567/ci03010006
Yuan Gu, Ziyang Wang, Yuli Wang, Yishu Gong, Chen Li
{"title":"Exploring Longitudinal MRI-Based Deep Learning Analysis in Parkinson’s Patients - A Short Survey Focus on Handedness","authors":"Yuan Gu, Ziyang Wang, Yuli Wang, Yishu Gong, Chen Li","doi":"10.58567/ci03010006","DOIUrl":"https://doi.org/10.58567/ci03010006","url":null,"abstract":"<p class=\"MsoNormal\" style=\"text-align: justify;\"><span lang=\"EN-US\" style=\"mso-bidi-font-size: 10.5pt; font-family: Nunito; color: #212529; background: white;\">Parkinson’s Disease (PD) is a prevalent progressive neurodegenerative condition affecting millions globally. Research has found that individuals with PD have a reduced risk of certain cancers, such as colon, lung, and rectal cancers, but an increased risk of brain cancer. Therefore, there is an urgent need for the development of advanced PD diagnostic methods and for investigating the relationships between risk factors, such as lifestyle due to handedness associated with various types of cancers. Recent ad- vancements in magnetic resonance imaging have enhanced PD diagnosis, reducing misdiagnosis and facilitating more accurate disease progression monitoring. Nevertheless, challenges exist, particularly in the distinction of PD between left-handed and right-handed patients over time. This survey provides an overview of contemporary deep learning-based imag- ing analysis methodologies, encompassing both non-longitudinal and lon- gitudinal contexts. We also explore existing limitations and prospects for refinement to gain deeper insights. These insights are poised to inform the development of personalized treatment strategies for PD patients while elucidating the current disparities between deep learning models and their efficacious implementation in clinical practice.</span></p>","PeriodicalId":476544,"journal":{"name":"Cancer Insight","volume":"17 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140239199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer InsightPub Date : 2024-01-02DOI: 10.58567/ci02020008
Shivakumar Sonnaila, Shilpi Agrawal
{"title":"CRISPR-Cas9 Unleashed: Gene-Slicing Adventures in the Cancer Battlefield","authors":"Shivakumar Sonnaila, Shilpi Agrawal","doi":"10.58567/ci02020008","DOIUrl":"https://doi.org/10.58567/ci02020008","url":null,"abstract":"Cancer, a global health menace, continues to pose significant challenges in terms of incidence and mortality, necessitating innovative therapeutic strategies. Despite existing treatments, the limitations persist, prompting a quest for novel approaches. The emergence of immunotherapy marked a transformative era in solid tumor treatments, yet its efficacy is constrained by adverse effects. Concurrently, the integration of advanced technologies into cancer treatment explores the vast potential residing at the molecular level through gene analysis and manipulation. This review articulates the role of state-of-the-art genome editing technology, notably clustered regularly interspaced short palindromic repeats (CRISPR-Cas9), in overcoming the constraints of immunotherapy for cancers. Unveiling the intricacies of CRISPR-Cas9-mediated genome editing, the review introduces the formidable CRISPR toolbox. A spotlight is cast on the transformative impact of CRISPR-induced double-strand breaks (DSBs) on cancer immunotherapy, encompassing knockout and knock-in strategies. The utilization of CRISPR/Cas9 technology in pre-clinical cancer research has demonstrated notable success; however, its transition to the clinical setting remains in the nascent stages of development. This review aims to elucidate the fundamental aspects of CRISPR technology and offer a comprehensive survey of its existing applications while outlining its prospective role in the realm of cancer therapies. Through an exploration of CRISPR's mechanisms, current applications, and anticipated future potentials, this review provides valuable insights into the evolving landscape of CRISPR-based cancer treatment strategies.","PeriodicalId":476544,"journal":{"name":"Cancer Insight","volume":"116 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139391540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}